 |
 |

Medullary Carcinoma in ChildrenResults of Early Detection and Surgery
Robert L. Telander, MD;
Donald Zimmerman, MD;
Glen W. Sizemore, MD;
Jon A. van Heerden, MB, ChB;
Clive S. Grant, MD
Arch Surg. 1989;124(7):841-843.
Abstract
 |  |
Early diagnosis and surgical treatment of medullary carcinoma of the thyroid (MCT) in children is essential to decrease the likelihood of metastatic spread. To determine the optimal timing of screening and surgery, we reviewed all children younger than 16 years old who were undergoing surgical treatment. From 1970 to 1988,33 children 6 months old to 15.9 years old (mean, 9 years old) with MCT or C-cell hyperplasia or both underwent total thyroidectomy. Follow-up was 4 months to 15 years after surgery (mean, 9 years). Six of 31 patients presented with a neck mass. Basal immunoreactive calcitonin level was increased in 3 of 7 patients with C-cell hyperplasia alone, in 10 of 18 patients with nonmetastatic MCT, and in all 5 patients with metastatic MCT. At the time of surgery, 7 patients had C-cell hyperplasia, 19 patients had MCT without metastasis, and 7 patients had MCT with metastases. All children with metastasis were more than 12 years old. Medullary carcinoma of the thyroid was seen as early as age 6 months in a child with multiple endocrine neoplasia type IIb (MEN-IIb) and age 3 years in a child with MEN-IIa. At follow-up, 25 patients were free of disease and 8 had had recurrent disease. Two of the 8 patients with MEN-IIb had died. All 6 children with a neck mass at presentation had recurrent disease. Of 27 patients diagnosed by screening, 25 had no evident disease and 2 had persistent disease. Thus, in children with MEN-II syndromes, screening studies are highly effective in detecting MCT. All children with MEN-IIb should be studied shortly after birth, and those with MEN-IIa should be studied by 1 year old.
(Arch Surg. 1989;124:841-843)
Author Affiliations
From the Section of Pediatric Surgery (Dr Telander), the Department of Pediatrics (Dr Zimmerman), the Division of Endocrinology, Metabolism, and Internal Medicine (Dr Sizemore), and the Section of Gastroenterologic and General Surgery (Drs van Heerden and Grant), Mayo Clinic and Mayo Foundation, Rochester, Minn. Dr Sizemore is now with the Section of Endocrinology, Loyola University Medical Center, Maywood, Ill.
Footnotes
Accepted for publication April 3, 1989.
Read before the 96th Annual Meeting of the Western Surgical Association, San Diego, Calif, November 15, 1988.
Reprint requests to Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Dr Zimmerman).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Review of Multiple Endocrine Neoplasia Type 2A in Children: Therapeutic Results of Early Thyroidectomy and Prognostic Value of Codon Analysis
Szinnai et al.
Pediatrics 2003;111:e132-139.
ABSTRACT
| FULL TEXT
Genotype-Phenotype Correlations in Hereditary Medullary Thyroid Carcinoma: Oncological Features and Biochemical Properties
Machens et al.
J. Clin. Endocrinol. Metab. 2001;86:1104-1109.
ABSTRACT
| FULL TEXT
Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis
Hansford and Mulligan
J. Med. Genet. 2000;37:817-827.
ABSTRACT
| FULL TEXT
Thyroid Cancer: A Lethal Endocrine Neoplasm
Robbins et al.
ANN INTERN MED 1991;115:133-147.
ABSTRACT
|